Xiaoxia Chen
Research Subjects
Xiaoxia Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Hongmei Yang
1 shared publicationJian Lin
1 shared publicationJichao Qin
1 shared publicationMuren Hu
1 shared publicationQingqing Feng
1 shared publication- Qingqing Zhou
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Programmable Nucleic Acid Nanospheres Coordinate Lactate Modulation and cGAS-STING Signaling Activation to Enhance Antitumor Immunity
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgrammable Nucleic Acid Nanospheres Coordinate Lactate Modulation and cGAS-STING Signaling Activation to Enhance Antitumor Immunity
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.